Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas (PREVENT)

Inclusion Criteria: Men and women with non-segmental vitiligo. ≥ 18 and <80 years. At least one pair bilateral of stable vitiligo lesions with a surface >2cm² and < 20cm², located outside the face unresponsive to medical treatment For women of child-bearing age, an effective contraception (estroprogestative pill, contraceptive implant, IUD, condoms or tubal ligation) should be used for more than one month before the inclusion in the study. A urine pregnancy test (βHCG in urines) will be performed. Affiliation to a social security system Signed informed consent Participants who agree to discontinue all agents used to treat vitiligo from screening through the final safety follow-up visit. Exclusion Criteria: Pregnant or breast-feeding women. Or women who plan to get pregnant during the study duration. Segmental or mixed vitiligo Vitiligo lesions located only on face, feet, or fingers. (dorsum of the hand accepted). Concomitant use of topical or systemic immunosuppressive medication or steroids Previous treatment with topical ruxolitinib cream or any systemic JAK inhibitor Areas that have already received surgical grafting Patients suffering from photodermatosis or taking photosensitive drugs Medical history of hypertrophic scars or keloids Medical history of skin cancer on the site to be treated Allergy to ruxolitinib cream, xylocaine or hyaluronic acid or trypsin (Viticell® must not be utilised with patients who are hypersensitive to hyaluronic acid or trypsin) Active infection Patients with thromboembolic risk Any dermatosis located on the treated site that could interfere with the evaluation of the treatment Vulnerable people: pregnant or breast-feeding women, minors, adult under guardianship or deprived of freedom Participants in other clinical therapeutic studies involving a drug that could interfere with the present evaluation Participants with active acute bacterial, fungal, or viral skin infection within 1 week before baseline; Participants with concurrent malignant disease or a history of that in the 5 years preceding the baseline visit except for adequately treated non metastatic malignancies; Participants with current and/or history of liver disease, including known hepatitis B or C, with hepatic or biliary abnormalities; Participants with current and/or history of tuberculosis; Participants who have used depigmentation treatments for past treatment of vitiligo or other pigmented areas. Patient under guardianship or curatorship